Trial Profile
Safety and efficacy of single-dose of fosaprepitant combined with ondansetron versus ondansetron for the prevention of chemotherapy induced nausea and vomiting in pediatric patients with hematooncological malignancies after moderate and high emetogenic chemotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2017
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary) ; Ondansetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Therapeutic Use
- 22 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology